Omeros Corporation Stock Price and Value Analysis

Omeros Corporation (NasdaqGM:OMER) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Omeros Corporation to reach your target.

Target type

OMER Free Cash Flow Trend

Free Cash Flow trendline for OMER
Free Cash Flow trendline for Omeros Corporation

Hmm, we can't give any reliable projection for Omeros Corporation's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the OMER Numbers

OMER Price
(Omeros Corporation stock price per share)
$13.21
[?] PE Ratio versus Sector 21% lower than other Healthcare stocks
[?] PE Ratio versus Industry 98% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 77%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 12,833,757 shares shorted. With 71,361,419 shares available for purchase and an average trading volume over the past 10 trading days of 1,547,650, it would take at least 8.3 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 2 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled -$196 million against net income of $242 million, or -0.81 times. Net income was negative in 15 of the 17 years, and those years are left out of the ratio.

In 2025, net income was -$3.4 million and operating cash flow was -$116 million, so no ratio is shown for that year.

In 2023, capital expenditures were $0.4 million, 0.6% of operating cash flow of $74.7 million, which leaves an estimated $74.3 million after capex. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 -21.1 -19 0.3 n/a
2010 -29.3 -14.5 0.8 n/a
2011 -28.5 -25.7 1.2 n/a
2012 -38.4 -34.6 0.6 n/a
2013 -39.8 -29.7 0.2 n/a
2014 -73.7 -58 0 n/a
2015 -75.1 -65.2 0.2 n/a
2016 -66.7 -51.5 0.1 n/a
2017 -53.5 -36.2 0.3 n/a
2018 -127 -104 0.6 n/a
2019 -84.5 -60.1 0.3 n/a
2020 -138 -100 0.3 n/a
2021 194 -110 0.3 -0.56
2022 47.4 -86.5 0.1 -1.82
2023 -118 74.7 0.4 n/a
2024 -157 -149 0.2 n/a
2025 -3.4 -116 0.1 n/a

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $9.7 million against total liabilities of $447 million, or 2.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 137.2% of total assets in 2025, compared with 55.2% in 2010, an increase of 82.0 percentage points.

Stockholders equity was negative in 2025, at -$121 million, which means the company's liabilities and other claims on its assets exceeded the assets themselves. Companies that return cash through large buybacks can show negative equity for that reason alone, but it also leaves no book value cushion for shareholders.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -48.9% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 45.7 3.3 25.2 20.5
2011 27 4 32.5 -5.6
2012 26.6 1.5 33.1 -6.5
2013 16.5 1.4 34.9 -18.4
2014 10.8 0.4 53.5 -42.7
2015 49 1.4 75.2 -26.2
2016 67.3 2.2 105 -37.4
2017 116 3.4 119 -2.8
2018 95.9 5.9 196 -100
2019 137 3.1 246 -109
2020 181 10.5 302 -121
2021 419 101 395 23.8
2022 591 11 505 85.7
2023 378 7.1 403 -25
2024 277 3.4 460 -183
2025 326 9.7 447 -121

Price Versus Our Estimated Value

Free cash flow was positive in 1 out of 17 reported years for Omeros Corporation, using only its current SEC filer.

We do not estimate a fair value for Omeros Corporation while its free cash flow growth is not positive, so there is no value comparison here.

Year-to-year variability in free cash flow is volatile, measured at 77%.

We do not have a dividend yield for Omeros Corporation.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 21% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 98% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Omeros Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Omeros Corporation (OMER) 984 15.9 - - -
Collegium Pharmaceutical (COLL) 768 22.7 - - 155% above
Amphastar Pharmaceuticals (AMPH) 1,205 13.0 - 0.9% 98% above
Innoviva (INVA) 1,309 7.8 - - 12% above
Phibro Animal Health Corporation (PAHC) 1,352 13.9 1.4% - 82% above
ANI Pharmaceuticals (ANIP) 1,558 13.9 - - 188% above
SIGA Technologies (SIGA) 172 240.0 - 8.2% 87% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1285819.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 16 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: OMER annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in OMER

Does Omeros Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: OMER

This example shows how we apply the Trendshare checklist to OMER: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 13.21
    • Market cap: $984M
    • EPS: 0.83
  2. Step 2 — Valuation checks

    • P/E: 15.916
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.